Source comparison
CJC-1295 & Ipamorelin with Alcohol Safety: Full Comparison
Before the table: This comparison shows alcohol's impact across different consumption patterns and timing windows relative to peptide administration. The 'Mechanism of Interference' column explains how alcohol disrupts peptide efficacy at each level, and the '
This comparison does not assign a generated winner or score.
- Before the table: This comparison shows alcohol's impact across different consumption patterns and timing windows relative to peptide administration. The 'Mechanism of Interference' column explains how alcohol disrupts peptide efficacy at each level, and the 'Professional Assessment' column provides our direct take on risk vs. outcome.
- 0–2 hours before or after injection
- 1–2 standard drinks
- Direct GHRH suppression + somatostatin elevation in hypothalamus
- 50–70% reduction in GH pulse amplitude
- High interference. Peptides cannot function as intended; abstain entirely within this window
- 3–6 hours before injection
- Moderate somatostatin tone still elevated; hepatic IGF-1 synthesis reduced
- 30–50% reduction in GH response
- Moderate interference. Peptides partially effective but suboptimal
- 6–12 hours before injection
- 2–3 standard drinks
- Residual cortisol elevation; lingering inhibition of nocturnal GH pulsatility
- 20–40% reduction depending on individual metabolism
- Low-to-moderate interference. Timing improves outcomes but doesn't eliminate interaction
- 12+ hours before injection
- 1–2 standard drinks (previous day)
- Minimal acute endocrine disruption unless chronic consumption pattern
- <10% measurable impact on single-dose GH release
- Minimal interference. Peptide efficacy largely preserved
- Chronic consumption (≥3 drinks/week ongoing)
- Varies
- Chronic baseline suppression of GHRH tone; hepatic IGF-1 production chronically reduced
- 30–60% reduction in peptide therapy outcomes over weeks to months
- Chronic interference. Negates long-term peptide therapy benefits regardless of same-day timing